A Randomised, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects with Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis

Phase 3

Completed

Conditions: 10017969
inflammation of the ileal pouch
10017998

Registration Number: NL-OMON46082

Lead Sponsor: Atlantic Pharmaceuticals Ltd

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 8

Inclusion Criteria

DOUBLE-BLIND PHASE INCLUSION CRITERIA:
1. Written informed consent;
2. Male or female subjects, *18 years of age who have undergone an IPAA for UC
3. History of pouchitis
Documented evidence of active pouchitis, based on endoscopy, symptoms and histopathology, as follows:
4. Endoscopic score *2 on the endoscopic component of a modified MAYO score (where friability is scored as *2)
Note: the area within 1 cm of the pouch staple, or pouch suture line, is not considered evaluable
5. Symptomatic disease (stool frequency): Subjects must demonstrate increased stool frequency compared to what is considered *normal* after their IPAA operation (*baseline*). Stool frequency must be an absolute value of * 6 stools per day, and * 3 stools per day above the post-IPAA *baseline*.
Note: The measurement of stool frequency will be a 7-day average rounded to the nearest integer. The most recent 7 days of data will be used to calculate the average.
6. Histology: evidence of disease (Score * 2 on PDAI)
7. Overall PDAI score > 7
8. Must have Chronic Antibiotic Refractory Pouchitis
Chronic Antibiotic Refractory Pouchitis is defined as remaining in active disease despite antibiotic therapy for at least 2 continuous weeks. There is no requirement for antibiotic use to be current, or within a defined time-window. Antibiotics must be stopped 4 weeks before the Randomisation Visit, which is effectively 2 weeks before the Screening Visit. As a minimum the antibiotic regime will comprise ciprofloxacin 1g/day, or metronidazole 15 * 20 mg/kg/day. Subjects must have been in active disease for a minimum of 4 weeks at the point of randomisation.;4.1.1 OPEN LABEL ACCESS INCLUSION CRITERIA
1. Written informed consent;
2. Previous participation to Week 26 of double blind phase
3. Demonstrated compliance with previous alicaforsen/blinded treatment
4. Current evidence of active disease, based on clinical symptoms

Exclusion Criteria

DOUBLE-BLIND FASE EXCLUSION CRITERIA:
1. Lack of effective contraception
Women of childbearing potential may not participate unless they are surgically sterile or are using adequate contraception.
The following contraceptive methods are acceptable: hormonal (eg oral, injection, transdermal patch, implant, cervical ring), barrier (eg condom or diaphragm with spermicidal agent), intrauterine system or intrauterine device. If hormonal contraceptives are used by female subjects they must be established for 6 weeks before the first administration of test product. Male sterilization is considered an acceptable form of contraception if the appropriate post-vasectomy documentation (absence of sperm) is provided in the subject*s medical notes. Sexual abstinence is considered acceptable if this is in line with the preferred and usual lifestyle of the subject; periodic abstinence (eg calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
Male subjects with female partners of child-bearing potential and female subjects who are neither surgically sterilized nor post-menopausal (defined as no menses for one year or an FSH value > 40 IU/L) will be required to use effective contraception throughout the study and for 30 days after.
2. Women who are pregnant or breastfeeding;
3. History of allergy or adverse event to oligonucleotides including alicaforsen, hydroxymethylcellulose, methyl or propylparabens.
Stable use of concomitant medications for pouchitis is generally permitted, doses of concomitant medication, where taken, should be optimised in accordance with local/national practice guidelines, and dose levels and types of baseline medications for pouchitis will be documented and any changes during the study will be recorded. Changes in use of medications for pouchitis and high doses of oral steroids are not permitted. It is particularly important to maintain stable medication through to measurement of the primary end-point at Week 10. Criteria which would lead to exclusion of subjects from the study are described below:
4. Changes in dose to strong analgesia, such as opioid containing compounds within 4 weeks of
the Screening Visit.
5. History of regular NSAID use.
6. Oral 5-aminosalicylate (5-ASA) compounds; exclude subjects who have discontinued or changed doses of oral 5-ASA within 4 weeks of the Screening Visit.
7. Oral budesonide > 6.0 mg / day is not permitted; exclude subjects who have received budesonide for < 6 weeks, or who have changed doses of budesonide within 4 weeks of the Screening Visit.
8. Oral steroids other than budesonide; exclude subjects who exceed a daily dose of 15 mg prednisolone or equivalent, who have received oral steroids for < 6 weeks, or who have changed dose within 4 weeks of the Screening Visit.
9. Use of rectal compounds is not permitted; these agents must be discontinued at the Screening Visit.
10. Immunosuppressant therapy (azathioprine, 6-mercaptopurine, methotrexate, cyclosporin); exclude subjects who have received treatment for < 12 weeks, or who have changed doses within 8 weeks of the Screening Visit.
11. Biological agents: Anti-tumour necrosis factor (anti * TNF) therapy and / or vedolizumab; are not permitted within 8 weeks of the Screening Visit.
12. Previous use of alicaforsen is permitted: treatment course must have completed at least 12 weeks prior to the Screening Vis

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Co-Primary Endpoints :<br /><br>1. Proportion of subjects with endoscopic remission; defined as absence of<br /><br>friability and ulceration, represented by a score of <1 (endoscopy component of<br /><br>a modified MAYO score) at Week 10.<br /><br>Note : the area within 1 cm of the pouch suture line will not be included in<br /><br>the endoscopic evaluation.<br /><br>2. Proportion of subjects with a stool frequency represented by a MAYO subscore<br /><br>of *1 at Week 10.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary Endpoints:<br /><br>1. Percentage change in stool frequency from baseline compared to placebo; Week<br /><br>6 and Week 10.<br /><br>2. Change in urgency score from baseline compared to placebo; Week 6.<br /><br>3. Change in rectal bleeding score from baseline compared to placebo; Week<br /><br>6.<br /><br>4. Proportion of subjects who achieve overall PDAI <5 at both Week 6 and Week<br /><br>10.<br /><br>5. Mean change from baseline in CGQL at Week 6.<br /><br>6. Proportion of subjects by Week 26, who have not received additional<br /><br>treatment for pouchitis flares, since commencing study.</p><br>